Log in Free sign up

Verve Therapeutics (VERV) News and press releases

News

From Benzinga Pro

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves

Biotech, Earnings, M&A, News, Penny Stocks, Guidance, Health Care, Financing, Offerings, Small Cap, FDA, Management, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Verve Therapeutics Q1 EPS $(0.62) Up From $(4.99) YoY

Verve Therapeutics (NASDAQ:VERV) reported quarterly losses of $(0.62) per share. This is a 87.58 percent increase over losses of $(4.99) per share from the same period last year.

Verve Therapeutics Reports Clearance Of First VERVE-101 Trial Application

Biotech, News, FDA, General

Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023 Preparing for Submission of United Kingdom and United States Regulatory

Verve Therapeutics Reports Additional VERVE-101 And GalNAc-Lipid Nanoparticle Delivery Data In Non-Human Primates At TIDES USA 2022

Biotech, News, FDA, General

VERVE-101 Preclinical Data Package Supports Company’s Global Development Strategy and Regulatory Submissions for Clinical Trials in Patients with HeFH Single Intravenous Infusion of VERVE-101 Clinical Formulation

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 1043 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Thursday

News, Options, Intraday Update, Markets

During Thursday, 849 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

Wednesday's session saw 784 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.

Stocks That Hit 52-Week Lows On Monday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Monday, 721 companies achieved new lows for the year.

Stocks That Hit 52-Week Lows On Thursday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Thursday, 236 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Tuesday, 242 companies hit new 52-week lows.

Verve Therapeutics Reports Durable And Well-tolerated Editing Of ANGPTL3 Gene Out To More Than 20 Months In Non-human Primates For Potential Treatment Of Atherosclerotic Cardiovascular Disease

Biotech, News, FDA, General

Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, reported updated preclinical data in non-human primates (NHPs)

68 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Sonim Technologies, Inc. (NASDAQ: SONM) shares jumped 103.3% to settle at $1.22 on Tuesday after the company announced its XP8 smartphone has integrated with the Walkie Talkie in Microsoft Teams.

Stocks That Hit 52-Week Lows On Tuesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Tuesday's session, 454 stocks hit new 52-week lows.

38 Stocks Moving In Tuesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Press releases

From Benzinga Pro

Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results

Earnings, Press Releases

Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023 Preparing for Submission of United Kingdom and United States

Verve Therapeutics Reports Additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery Data in Non-Human Primates at TIDES USA 2022

News, Health Care, Press Releases

VERVE-101 Preclinical Data Package Supports Company's Global Development Strategy and Regulatory Submissions for Clinical Trials in Patients with HeFH Single Intravenous Infusion of VERVE-101 Clinical Formulation Led to

Verve Therapeutics to Participate in Upcoming May Investor Conferences

CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced that

Verve Therapeutics Presents Comprehensive Analyses of Off-target Editing Risk for VERVE-101 at Precision Genome Engineering Keystone Symposia

News, Press Releases

Extensive Analyses in Multiple Human Cell Types Demonstrate Minimal to No Off-target Editing Following VERVE-101 Treatment, Supporting its Planned Clinical Initiation in 2022 Whole Genome Sequencing at 500X Coverage of

Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular Disease

Press Releases, General

Updated Sequential Dosing Data Show Administration of PCSK9 Base Editor Followed by ANGPTL3 Base Editor is Well-Tolerated in NHPs Data to be Presented Today at the American College of Cardiology 71st Annual Scientific

Verve Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference

News, Press Releases

CAMBRIDGE, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results

Earnings, Press Releases

Significant Progress Anticipated in 2022 with Initiation of Clinical Trial for VERVE-101 and IND-enabling Studies for ANGPTL3 Program Presentations at Upcoming Scientific Conferences to Highlight Novel Base Editing